Cellular Signaling Pathways

Why This Matters

Cellular signaling pathways are the molecular language cells use to communicate. Understanding them is central to biophysics because they reveal how physical and chemical forces translate into biological responses. You're being tested on the biophysical principles underlying these pathways: receptor-ligand binding kinetics, conformational changes, phosphorylation cascades, and ion flux dynamics. These concepts connect directly to thermodynamics, membrane biophysics, and protein structure-function relationships that appear throughout the course.

Don't just memorize pathway names and components. Know what biophysical mechanism each pathway exploits, whether it's conformational switching in G proteins, enzymatic amplification through kinase cascades, or rapid ion conductance changes. When you can explain why a pathway uses a particular strategy (speed vs. amplification vs. specificity), you're thinking like a biophysicist.

---

Receptor-Mediated Conformational Switching

These pathways rely on ligand-induced conformational changes in membrane receptors to transmit signals across the plasma membrane. The binding event triggers structural rearrangements that propagate information without the signaling molecule ever entering the cell.

G Protein-Coupled Receptor (GPCR) Signaling

• Seven-transmembrane architecture: GPCRs thread through the membrane seven times. This topology means extracellular ligand binding can shift the arrangement of transmembrane helices, which repositions intracellular loops to activate heterotrimeric G proteins on the cytoplasmic side.
• G proteins act as molecular switches: They cycle between GDP-bound (inactive) and GTP-bound (active) states. The receptor acts as a guanine nucleotide exchange factor (GEF), promoting GDP-to-GTP exchange on the $G_\alpha$ subunit. Signal termination is built in because $G_\alpha$ has intrinsic GTPase activity that hydrolyzes GTP back to GDP. Regulators of G protein signaling (RGS proteins) accelerate this hydrolysis.
• Signal amplification through effector diversity: A single activated receptor can sequentially activate multiple G proteins during the time the ligand remains bound. Each active $G_\alpha$ then regulates effector enzymes like adenylyl cyclase or phospholipase C, so the signal fans out at every step.

Receptor Tyrosine Kinase (RTK) Signaling

• Ligand-induced dimerization: RTK activation requires two receptor monomers to come together upon ligand binding. This brings their intracellular kinase domains into close proximity for trans-autophosphorylation, where each monomer phosphorylates specific tyrosine residues on the other.
• Phosphotyrosine residues create docking sites: The newly phosphorylated tyrosines recruit signaling proteins containing SH2 or PTB domains. Different phosphotyrosine positions recruit different proteins, which is how a single receptor type can activate multiple downstream pathways with specificity.
• Dysregulation drives oncogenesis: Mutations causing constitutive RTK activation (ligand-independent dimerization or loss of autoinhibition) are among the most common drivers of cancer, making this pathway a major therapeutic target.

---

Phosphorylation Cascade Amplification

These pathways use sequential kinase activation to amplify signals and integrate multiple inputs. Each phosphorylation step can activate many downstream targets, creating exponential signal amplification.

MAPK/ERK Pathway

• Three-tiered kinase cascade: The pathway follows a conserved structure: MAP3K → MAP2K → MAPK (specifically Raf → MEK → ERK). Each kinase phosphorylates and activates many copies of the next, so the signal grows at every tier.
• Activated by RTKs through Ras: The small GTPase Ras connects receptor activation to the cascade. Like heterotrimeric G proteins, Ras is a molecular switch with intrinsic GTPase activity, but it's a single small protein (~21 kDa) rather than a heterotrimer. Adaptor proteins (Grb2 and SOS) link phosphorylated RTKs to Ras activation.
• Nuclear translocation regulates transcription: Phosphorylated ERK enters the nucleus to activate transcription factors controlling cell cycle progression and differentiation genes. This nuclear entry step is a key control point.

PI3K-Akt Pathway

• Lipid second messengers: PI3K phosphorylates the membrane lipid $PIP_2$ at the 3' position to generate $PIP_3$. This lipid stays in the membrane and recruits Akt (also called PKB) through its pleckstrin homology (PH) domain, bringing Akt to the membrane where it can be activated.
• Akt is a master regulator of cell survival: Once phosphorylated at Thr308 (by PDK1) and Ser473 (by mTORC2), Akt phosphorylates dozens of substrates controlling apoptosis, metabolism, and growth. For example, Akt phosphorylates and inactivates the pro-apoptotic protein BAD, promoting cell survival.
• PTEN provides negative regulation: This lipid phosphatase dephosphorylates $PIP_3$ back to $PIP_2$ by removing the 3' phosphate. Loss of PTEN function is one of the most frequent events in human cancers because it leaves the survival signal permanently elevated.

JAK-STAT Signaling Pathway

• Direct receptor-to-nucleus signaling: Unlike MAPK or PI3K pathways, JAK-STAT provides a relatively direct route from cytokine receptors to gene transcription with fewer intermediate steps. This makes it faster for transcriptional responses, though it sacrifices the amplification that multi-step cascades provide.
• Receptor dimerization activates JAKs: Cytokine binding brings receptor-associated Janus kinases (JAKs) together for trans-phosphorylation. Activated JAKs then phosphorylate tyrosine residues on the receptor's cytoplasmic tail, creating STAT docking sites.
• STAT dimerization enables DNA binding: Phosphorylated STATs form dimers through reciprocal SH2-phosphotyrosine interactions. These dimers are the functional transcription factor that translocates to the nucleus and binds specific DNA elements.

---

Second Messenger Systems

These pathways use small diffusible molecules to rapidly spread signals throughout the cell. Second messengers amplify signals and enable spatial distribution of information far from the original receptor.

cAMP Signaling Pathway

• Adenylyl cyclase generates cAMP from ATP: This membrane-bound enzyme is activated by $G_{\alpha s}$ proteins and inhibited by $G_{\alpha i}$ proteins, so it integrates multiple GPCR inputs into a single output. A single active adenylyl cyclase produces many cAMP molecules, adding another amplification layer.
• PKA activation requires cAMP binding: Protein kinase A exists as an inactive tetramer of two regulatory (R) and two catalytic (C) subunits. When two cAMP molecules bind each R subunit (four total), the R subunits release the active C subunits.
• Phosphodiesterases (PDEs) terminate signaling: These enzymes hydrolyze cAMP to AMP, and their activity determines signal duration. Caffeine inhibits certain phosphodiesterases, which is part of why it prolongs sympathetic-like signaling effects.

Calcium Signaling

• Steep concentration gradient enables rapid signaling: Cytosolic $Ca^{2+}$ is maintained at ~100 nM while extracellular and ER lumen concentrations reach 1-2 mM. That's a 10,000-fold gradient. This gradient is maintained by SERCA pumps (ER) and $Ca^{2+}$-ATPases (plasma membrane), and it means that simply opening a channel produces a large, fast signal with no synthesis required.
• Multiple release mechanisms: $Ca^{2+}$ can enter the cytoplasm through voltage-gated channels (neurons, muscle), ligand-gated channels (synapses), store-operated channels (STIM/Orai), or be released from ER stores via $IP_3$ receptors or ryanodine receptors.
• Calmodulin transduces calcium signals: Calmodulin undergoes a conformational change upon binding four $Ca^{2+}$ ions (two per EF-hand lobe), exposing hydrophobic surfaces that wrap around and activate target proteins like CaM kinase II (CaMKII) and calcineurin.

---

Rapid Ion Flux Signaling

This pathway exploits direct coupling between ligand binding and ion conductance for the fastest possible cellular responses. No enzymatic cascades or second messengers are involved, just immediate changes in membrane potential.

Ion Channel-Linked Receptor Signaling

• Ligand-gated channels combine receptor and effector: The receptor is the ion channel. Ligand binding directly opens the pore, eliminating intermediate steps and enabling responses within microseconds to milliseconds. The nicotinic acetylcholine receptor (nAChR) at the neuromuscular junction is the classic example.
• Ion selectivity determines response type: Channels selective for $Na^+$ or $Ca^{2+}$ cause depolarization (excitatory), while $Cl^-$-selective channels (like $GABA_A$ receptors) typically cause hyperpolarization (inhibitory). The selectivity filter's structure determines which ions pass.
• Desensitization limits signal duration: Prolonged agonist exposure causes conformational changes that close the channel pore despite continued ligand binding. This is a built-in negative feedback mechanism that prevents overstimulation and is distinct from simple ligand unbinding.

---

Transcription Factor Activation Pathways

These pathways regulate gene expression by controlling transcription factor activity or localization. The endpoint is changed patterns of protein synthesis, making these pathways slower (minutes to hours) but capable of sustained cellular reprogramming.

Wnt Signaling Pathway

• β-catenin stability is the key regulated step: Without Wnt ligand, a destruction complex (containing APC, Axin, CK1, and GSK3β) phosphorylates β-catenin, tagging it for ubiquitination and proteasomal degradation. Cytoplasmic β-catenin levels stay low.
• Wnt binding inhibits the destruction complex: Wnt binds the Frizzled receptor and LRP5/6 co-receptor. This recruits Dishevelled, which disrupts the destruction complex. β-catenin is no longer phosphorylated, so it accumulates in the cytoplasm and enters the nucleus.
• TCF/LEF transcription factors require β-catenin as a co-activator: Without β-catenin, TCF/LEF proteins sit on DNA and recruit co-repressors. When β-catenin binds, it displaces the repressors and recruits co-activators, switching on developmental gene programs.

NF-κB Signaling Pathway

• IκB sequesters NF-κB in the cytoplasm: The inhibitor IκB masks the nuclear localization signal (NLS) of NF-κB, keeping the transcription factor trapped and inactive under resting conditions.
• IKK phosphorylates IκB for degradation: Inflammatory signals (TNF, IL-1, LPS) activate the IκB kinase (IKK) complex. IKK phosphorylates IκB, which marks it for K48-linked ubiquitination and proteasomal degradation.
• Rapid nuclear translocation follows IκB loss: Once IκB is degraded, the NLS on NF-κB is exposed. NF-κB immediately enters the nucleus to activate genes for cytokines, chemokines, and anti-apoptotic proteins. One of its target genes is IκB itself, creating a negative feedback loop.

---

Quick Reference Table

---

Self-Check Questions

1. Both heterotrimeric G proteins and Ras function as GTPase molecular switches. How do they differ in structure (subunit composition, size) and in what regulates their GTPase activity (RGS proteins vs. GAPs)?

2. Compare the mechanisms by which cAMP and calcium function as second messengers. Why is calcium signaling faster, and what makes cAMP signaling more independently tunable at the synthesis and degradation levels?

3. If asked to explain signal amplification, trace the MAPK/ERK pathway from a single ligand binding event through each amplification step. At which tiers does the signal fan out, and why does a three-tiered cascade produce greater amplification than a single kinase step?

4. Both Wnt and NF-κB pathways regulate transcription factor nuclear entry. One stabilizes the transcription factor; the other destroys an inhibitor. Diagram the logic of each and explain why NF-κB signaling includes a built-in negative feedback loop.

5. A mutation causes a receptor tyrosine kinase to be constitutively active (always on, even without ligand). Which downstream pathways (MAPK/ERK, PI3K-Akt) would be affected, what cellular processes would be dysregulated, and why does this commonly lead to cancer?